drugset / Trial / NCT00321308

Trial of Pemetrexed With or Without PF-3512676 in Advanced Non-Small Cell Lung Cancer

NCT00321308

Phase 2 Terminated 36 enrolled Pfizer
RandomizedParallel-groupOpen-labelTreatment

Summary

To assess the efficacy and safety of PF-3512676 administered in combination with pemetrexed for the treatment of patients with locally advanced or metastatic NSCLC who have failed one prior chemotherapy regimen

Timeline

Start
2006-09
Primary completion
2008-01
Completion
2008-01

Drugs

EvaluationDrugModalityDoseRoute
Subject agatolimod Oligonucleotide (other)
Comparator Pemetrexed Small molecule 500 mg/m2 Intravenous